303 results about "IV Chemotherapy" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

A hybrid liver cancer prognosis model, prognosis system and medium, the model takes independent influence factors as input and outputs hybrid liver cancer postoperative risk scores, the hybrid liver cancer postoperative risk scores are used for dividing risk levels, and the risk levels are used for hybrid liver cancer prognosis evaluation. And / or is used for postoperative adjuvant chemotherapy decision-making of mixed liver cancer. The hybrid liver cancer prognosis model is jointly constructed by combining the traditional clinical pathological characteristics and immune microenvironment indexes, the key effect of the tumor immune microenvironment in CHC prognosis is indicated, and the constructed hybrid liver cancer prognosis model has good CHC prognosis prediction performance; in addition, decisions of postoperative adjuvant chemotherapy can be provided for patients with different risk levels, precise treatment of the CHC patients is achieved, and long-term survival prognosis of the CHC patients is improved.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention provides a multifunctional intelligent anti-thrombus PICC (peripherally inserted central catheter) for tumor chemotherapy, which comprises a catheter body, a catheter tip, a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity, and the first auxiliary cavity and the second auxiliary cavity are arranged around the main infusion cavity to form a spiral structure; a micro pressure sensor array is embedded in the pipe wall of the first auxiliary cavity; a biological impedance measuring electrode pair is embedded in the pipe wall of the second auxiliary cavity; and the micro pressure sensor array, the biological impedance measuring electrode pair, the micro ultrasonic transducer and the temperature sensor are connected with a processor. According to the method, active thrombus prevention is achieved, passive treatment is changed into active prevention through a triple mechanism, and the thrombus occurrence rate is greatly reduced; meanwhile, the tube body is formed by mutually winding, fusing and extruding three independent cavities (a main infusion cavity, a first auxiliary cavity and a second auxiliary cavity) like a DNA double helix (triple helix is provided herein); and the mechanical stimulation and damage to the inner wall of the blood vessel are reduced.

The invention relates to the technical field of gastrointestinal tumor chemotherapy risk assessment, and particularly discloses a gastrointestinal tumor chemotherapy risk scoring model and a construction method thereof, and the method comprises the steps: obtaining the individualized feature data and basic physiological data of a historical patient, and constructing an individualized difference library with a unique ID, and a core influence library; the method comprises the following steps: standardizing and coding double-library data, synchronizing clinical data containing treatment effect codes, forming a data dictionary, acquiring and coding current gastrointestinal tumor patient data, and matching the data dictionary to judge individual difference abnormity; when the first data set is abnormal, constructing a first data set, screening core independent variables through Logistic regression, and constructing a scoring model by using an LSTM (Long Short Term Memory) model; when no abnormity exists, redundant codes are removed to obtain a second data set, and modeling is conducted through the same method. Through double-library linkage and scene-divided modeling, the three-level toxicity risk prediction precision is improved, data support is provided for clinical chemotherapy dose adjustment and toxicity prevention, and the risk of excessive treatment or insufficient treatment is reduced.

The utility model belongs to the technical field of medical equipment, and discloses a vomiting relieving treatment device for tumor chemotherapy, which comprises a massage module, a fastening mechanism is arranged on the outer wall of the massage module, and a rolling mechanism is arranged on the outer wall of the massage module; the winding mechanism comprises a winding drum, a partition plate is fixedly connected to the inner wall of the winding drum, a rotating shaft is elastically connected to the outer wall of the partition plate through a volute spiral spring, a clamping groove is formed in the outer wall of the rotating shaft, a fixing block is fixedly connected to the outer wall of the front end of the winding drum, and a limiting block is elastically connected to the inner wall of the fixing block through a connecting spring. The pull-out length of the bandage can be fixed through clamping connection of the limiting block and the clamping groove, limiting of the rotating shaft is removed when the bandage is not used, the bandage can be automatically wound in the winding barrel, space is saved, and the problems that the bandage is wound disorderly due to the fact that the bandage is exposed all the time, and the bandage is inconvenient to tidy in the using process are solved.

The invention discloses application of circFAM126A in preparation of a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the technical field of molecular biology. According to the application disclosed by the invention, by constructing a lentivirus for targeted interference of novel circFAM126A and transfecting gastric cancer cells, it is proved that the lentivirus carrying a specific interference sequence can stably knock down circFAM126A expression in the gastric cancer cells, the drug resistance of the gastric cancer cells to oxaliplatin is effectively reversed, the tumor cell death effect induced by chemotherapeutic drugs is remarkably enhanced, and the tumor cell death effect is remarkably improved. Meanwhile, the proliferation and clone formation capability of gastric cancer cells is inhibited. Meanwhile, it is found that circFAM126A is highly expressed in oxaliplatin-resistant gastric cancer cells and is in positive correlation with poor prognosis of gastric cancer patients, a detection reagent aiming at circFAM126A can be used for auxiliary diagnosis of gastric cancer prognosis conditions, and the drug resistance degree of the gastric cancer cells to oxaliplatin can be evaluated by detecting the expression level of circFAM126A.

The invention discloses a platinum (IV)-pirfenidone compound prodrug, a preparation method and microenvironment remodeling anti-tumor application, and belongs to the field of medical technology and drug synthesis. A series of molecules are characterized by being platinum prodrugs modified by pirfenidone derivatives. The synthesis method sequentially comprises the following steps: oxidizing platinum drugs, modifying hydroxyl groups, and introducing pirfenidone derivatives through esterification reaction. A series of molecules are reduced into Pt (II) drugs at the focus to kill cancer cells, and meanwhile, the released pirfenidone derivative can remodel the tumor microenvironment. The platinum prodrug disclosed by the invention not only has excellent cancer cell killing ability, but also is relatively low in drug resistance and excellent in safety, can trigger immunogenic cell death, and is a brand new chemotherapy-immunotherapy method. A series of molecules are convenient to synthesize, the preparation process is simple, and the amphipathicity is excellent, the anti-cancer capability is excellent, the drug resistance and toxicity are low, and the clinical application prospect is good.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug- resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.

The invention relates to the technical field of medical care, and discloses a chemotherapy nursing device for medical oncology, comprising: an infusion seat for infusion; the lower annular plate is arranged at the top of the infusion seat; the upper ring plate is arranged at the top of the lower ring plate; the diaphragm is arranged in the upper annular plate; the inner sealing piece is arranged on the inner side of the lower annular plate and used for connecting the lower annular plate with the inner wall of the upper annular plate; and the outer sealing piece is arranged on the outer side of the lower annular plate. Positioning of the upper annular plate by a positioning assembly is omitted, so that the position of the upper annular plate can be adjusted, the position of the diaphragm can be adjusted, the central needle inserting position of the diaphragm can avoid a disease skin area, normal needle inserting can be guaranteed, the upper annular plate is heated through a heating ring, and the needle inserting efficiency is improved. And heat is transferred to the skin, so that the skin cannot be tightened due to coldness, and the upper ring plate can be easily pushed subsequently.

The invention discloses an application of a reagent for detecting AP3S2 in preparation of a diagnostic reagent for neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, which comprises the following steps: screening differential expression proteins in neoadjuvant immunochemotherapy resistance tissues of gastric cancer in the local progression stage through proteomics; a new marker is provided for diagnosis of the local progression stage gastric cancer immunochemotherapy drug resistance, and a basis is also provided for development and future development of a local progression stage gastric cancer immunochemotherapy drug resistance diagnosis method.

The present application relates to the technical field of biological medicine, and discloses inhalable aptamer modified molybdenum disulfide nanoflower compound and application thereof.The compound comprises a molybdenum disulfide nanoflower core, a dendritic polylysine modification layer attached to the surface of the molybdenum disulfide nanoflower, doxorubicin loaded on the molybdenum disulfide nanoflower and / or the dendritic polylysine modification layer, and AS1411 aptamer combined on the outer surface of the dendritic polylysine modification layer by electrostatic assembly.The compound can be delivered to a lung lesion by atomization inhalation or aerosol inhalation, and undergoes responsive structural change under the action of hydrogen peroxide in a tumor microenvironment, generates active oxygen, and promotes the release of doxorubicin, so as to realize the synergistic antitumor effect of chemotherapy and chemical dynamic therapy.The compound has good colloidal stability, drug loading capacity, active targeting ability and lung local delivery potential, and can be used for preparing inhalation preparations or local administration preparations for treating lung cancer.

This invention discloses a hydrogel for tumor treatment based on improving the tumor microenvironment to trigger gas therapy combined with chemotherapy, belonging to the field of biomedical technology. The hydrogel drug delivery system utilizes lipopolysaccharide (LPS) to induce local inflammatory stimulation, thereby altering the tumor microenvironment of breast cancer and promoting nitric oxide (NO) production. The NO donor arginine (L-Arg) and the chemotherapy drug doxorubicin (DOX) are transported using sodium alginate (ALG), achieving combined gas therapy and chemotherapy to inhibit breast tumor growth. The drug delivery system of this invention not only enhances the effect of chemotherapy but also simultaneously achieves precise drug delivery and reduces drug dosage. The preparation method of the drug delivery system of this invention is simple, safe, and without toxic side effects, showing promising application prospects in tumor treatment and possessing significant clinical value.

The invention relates to the technical field of tumor chemotherapy, in particular to a nursing device used after tumor chemotherapy. According to the technical scheme, the nursing frame comprises a nursing frame body, a fixing frame and a supporting frame, the lower surface of the nursing frame body is connected with a sleeve frame, the upper surface of the nursing frame body is sleeved with the fixing frame, a fixing rod is fixed to the outer end face of one side of the fixing frame, and the outer end face of one side of the fixing rod is rotationally connected with a connecting bearing; a movable frame is rotationally connected to the outer end face of one side of the connecting bearing, a rotating plate is connected to the outer end face of one side of the movable frame, a mounting frame is connected to the lower surface of the supporting frame, a connecting frame sleeves the upper surface of the supporting frame, and a movable bearing is fixed to the outer end face of one side of the connecting frame; a rotating frame is rotationally connected to the outer end face of one side of the movable bearing, and massage layers are fixed to the inner walls of the nursing frame body, the sleeve frame, the supporting frame and the mounting frame. According to the invention, varicosity of a patient can be prevented, and liquid medicine exosmosis and phlebitis incidence rate can be reduced.

The invention particularly relates to a perfusion chemotherapy dispensing device for medical oncology. A perfusion chemotherapy dispensing device for medical oncology comprises a shell and the like, a cover plate is fixedly arranged at the top of the shell, a control panel is installed on the front side of the cover plate, a plurality of containing pipes are fixedly connected to the front side of the cover plate at intervals, medicament bottles are placed in the containing pipes, and a storage assembly used for refrigerating and storing medicaments is arranged at the top of a bottom panel of the shell. The storage assembly and the side wall of the shell are jointly provided with a negative pressure suction assembly, and the negative pressure suction assembly is used for sucking the medicament in the medicament bottle into the storage assembly under the closed condition. According to the device, automatic medicament extraction is achieved, manual extraction is avoided, medicament exposure is reduced, the occupational exposure risk of medical staff is reduced, quantitative injection and stirring mixing are achieved, accurate and efficient dispensing is guaranteed, medicaments can be stored in a pre-filling mode, use is convenient and rapid, the stirring barrel can be cleaned, different medicaments can be prepared conveniently, and medicament waste and efficacy loss are reduced.

The application discloses a medical hollow tube positioning and marking device and belongs to the technical field of breast tumor marking. The device comprises a head, a fixing ring, an inner core, a hollow flexible tube and a needle cylinder. The fixing ring is fixed at intervals on the hollow flexible tube to form a long chain. The head is fixed at the head end of the long chain to form a marking body. The inner core penetrates into the hollow flexible tube to the head end to push the marking body to move in the needle cylinder. The front end of the needle cylinder is provided with a needle part. After puncture, the needle cylinder and the inner core are used to push the head outward and the marking body is pushed out and positioned. The marking body exposed outside is cut off. Multi-directional marking is used to form stereoscopic, linear and visual positioning. The marking body can be freely bent and is not easy to be cut off and displaced. The risk of infection or accidental injury caused by a traditional positioning steel wire is reduced. Breast cancer patients receiving neoadjuvant chemotherapy only need to be positioned and marked once and do not need to bear the secondary trauma of steel wire positioning again after traditional marking clamp marking.

The present disclosure relates to 1-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl)-4- hydroxypyrrolidine-2-carboxamide derivatives and structurally related compounds of formula (I) as VHL inhibitors for the treatment of e.g. anemia (e.g. chronic anemia or anemia associated with chronic kidney disease, dialysis or cancer chemotherapy), ischemia, stroke or injury to the cardiovascular system during ischemia, or for enhancing wound healing, reducing scarring or enhancing angiogenesis or arteriogenesis.

The invention discloses a risk score prediction curve of objective remission rate (ORR), disease control rate (DCR), progression-free lifetime (PFS) and total lifetime (OS) of a patient with advanced gastric or gastroesophageal junction adenocarcinoma after first-line chemotherapy and immunotherapy based on clinical inflammation indexes and application of the risk score prediction curve. The risk score is established based on clinical inflammation indexes and used for drawing a prediction curve of PFS and OS after first-line chemotherapy and immunotherapy and ORR and DCR, common inflammation-related laboratory indexes are integrated, the calculation method is simple, and clinical doctors and patients can conveniently operate to predict ORR, DCR, PFS and OS after treatment. Meanwhile, the risk score prediction model can provide certain help for selection of treatment schemes of later gastric or gastroesophageal junction adenocarcinoma patients in the future.

The invention discloses application of cucurbitacine I in preparation of cisplatin sensitization drugs for treating ovarian cancer, and belongs to the technical field of sensitization drugs for tumor chemotherapy. CuI and CDDP have a good synergistic tumor inhibition effect on ovarian cancer, CuI may directly act on EGFR and can be combined with CDDP to significantly inhibit phosphorylation of EGFR and downstream STAT3 protein thereof, induce DNA damage and ROS accumulation, amplify a pyroptosis effect, increase release of TAAs and DAMPs, promote DC maturation and promote infiltration of CD8 + T cells and memory T cells in TIME in vivo, so that the tumor inhibition effect on ovarian cancer is improved. The expression of an inhibitory costimulatory molecule PD-1 in CD8 + T cells is reduced, the whole body immune effect is activated, and the TIME of the ovarian cancer is remarkably improved. The combined treatment strategy of CuI-CDDP controls the progress of ovarian cancer from a dual mechanism of directly inhibiting tumor cells and promoting anti-tumor immune activation.

The invention relates to a device and method for thermal therapy of a selected region of a human or animal body, particularly for treating tissue damage after surgery, injuries, inflammation, chronic rheumatic conditions, and for supporting chemotherapy. The system includes a temperature control device that circulates a temperature-controlled fluid through a heat transfer unit configured for uniform skin contact, and a pressure device to optimize thermal transfer. During chemotherapy, the device maintains the selected region, such as hands or feet, at a target temperature to prevent or reduce chemotherapy-induced polyneuropathy (CIPN). Sensors monitor temperature and pressure, enabling feedback control for consistent therapy. Methods include fitting the device to the patient, adjusting pressure, and maintaining even skin cooling throughout chemotherapy, thereby improving patient comfort, reducing adverse side effects, and supporting adherence to treatment. The invention provides improved outcomes in thermal therapy applications.

The application of PDPN in the treatment of gemcitabine-resistant pancreatic cancer belongs to the field of biological medicine, and the application of PDPN in the preparation of a reagent for detecting a gemcitabine-resistant pancreatic cancer product. The application of PDPN in the preparation of a drug for treating gemcitabine-resistant pancreatic cancer or increasing the sensitivity of pancreatic cancer to gemcitabine treatment. The application of PDPN in constructing a subcutaneous transplantation tumor cell model of gemcitabine-resistant pancreatic cancer and in constructing an orthotopic transplantation tumor model of gemcitabine-resistant pancreatic cancer. It is found through research that changing the expression level of PDPN can affect the sensitivity of gemcitabine-resistant pancreatic cancer cells to gemcitabine chemotherapy, which indicates that PDPN can be applied to the treatment and detection of gemcitabine-resistant pancreatic cancer.

The invention relates to the field of chemotherapy benefit analysis, in particular to a gastric cancer chemotherapy benefit analysis method and system based on multi-index calculation. The method comprises the following steps: extracting multi-temporal biomarkers of a patient in different treatment cycles, and carrying out nonlinear change trend analysis to obtain trend characteristics of the biomarkers; collecting drug monitoring parameters in a chemotherapy cycle, performing drug metabolism simulation according to the trend characteristics of the biomarkers, and constructing a drug synchronous kinetic model; the method comprises the following steps: extracting vital sign information and chemotherapy toxic reaction information of a patient based on clinical detection, performing chemotherapy safety boundary prediction, and generating chemotherapy tolerance assessment data; and performing chemotherapy benefit hierarchical calculation based on the chemotherapy tolerance evaluation data and the drug synchronous kinetic model to generate multiple levels of chemotherapy benefit indexes. According to the method, accurate and efficient gastric cancer chemotherapy benefit calculation is realized, and the cost performance and efficiency of treatment are improved.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

The invention relates to the technical field of evaluation of heart rehabilitation curative effects of breast cancer chemotherapy patients, in particular to a method and system for evaluating the heart rehabilitation curative effects of the breast cancer chemotherapy patients, and the method comprises the following steps: continuously obtaining heart rate variability data and skin conductance data of the breast cancer chemotherapy patients; based on the heart rate variability data and the skin conductance data, the activation state of the autonomic nervous system of the patient is judged; according to the activation state of the autonomic nervous system of the patient, quantifying the intensity and duration of the internal emotional state of the patient, and generating an emotional energy index; when the conventional physiological indexes of the patient fluctuate, determining a physiological fluctuation attribution result in combination with the emotional energy index to distinguish whether the physiological fluctuation is derived from heart function change or emotional influence; and evaluating the cardiac rehabilitation effect of the patient based on the physiological fluctuation attribution result. The accuracy of heart rehabilitation curative effect evaluation can be improved.

The invention discloses a sealing negative pressure protection device for abdominal cavity hyperthermic perfusion chemotherapy in laparotomy, and belongs to the technical field of medical instruments, the sealing negative pressure protection device comprises a protection cover body, the protection cover body is of a three-layer structure and sequentially comprises a porous breathable layer, a middle adsorption layer and a sealing supporting layer from inside to outside, and a circle of medical pressure-sensitive adhesive is arranged on the edge of the inner layer of the protection cover body; a negative pressure connector is arranged at the top of the protective cover body and used for being connected with external negative pressure equipment, two hanging rods are perpendicularly fixed to the inner layer of the protective cover body, telescopic supporting structures are fixed to the bottom ends of the two hanging rods, and a plurality of liquid inlet holes and liquid outlet holes are further formed in the protective cover body. The supporting assembly is integrated on the inner side of the protective cover body, and the problems that the compatibility of the surgical retractor and a sealing rubber strip on the edge of the protective cover body is poor, and gaps are likely to be generated are solved; by arranging the negative pressure connector and the middle adsorption layer, dual treatment of aerosol is achieved, and the occupational exposure risk of medical staff is reduced.

The present invention provides a novel means usable for predicting a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, said means being characterized by use of blood CD8-positive effector memory T cells as a biomarker. Specifically, in order to predict a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, (i) the level of CD8-positive effector memory T cells that are contained in a blood sample which is collected from the pancreatic cancer patient is measured and (ii) when the level of the CD8-positive effector memory T cells is high, it is determined that the therapeutic effect yielded by the combination therapy is high.

The application discloses application of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma. The application is based on a series of molecular biology experiments, and reveals that high expression of MNT inhibits ferroptosis of lung adenocarcinoma and increases chemotherapy sensitivity. Based on the results of the molecular biology experiments, the application first proposes a new use of MNT in detection of ferroptosis and chemotherapy sensitivity of lung adenocarcinoma; the expression amount of MNT of lung adenocarcinoma is detected to judge the sensitivity of lung adenocarcinoma patients to ferroptosis inducer and chemotherapy treatment, and the method has the advantages of simple operation, high sensitivity, specificity, high cost performance and application value, and provides a new way for clinically evaluating the sensitivity of lung adenocarcinoma patients to ferroptosis and cisplatin treatment.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.